Circulating Biomarkers of Cardiopulmonary Disturbances in COVID-19-Reference-Cited by-同舟云学术

Circulating Biomarkers of Cardiopulmonary Disturbances in COVID-19

Published:2023-01-04 Issue: Volume: Page:99-112
ISSN:2737-5633
Container-title:Coronaviruses
language:
Short-container-title:

Author:

Daemi Amin¹,Shabestari Alireza Mohammadzadeh²,Tirabadi Nahid Mirzaei³,Hosseini Seyyedeh Touran⁴,Fathi Mohammad⁵,Döğüş Yusuf⁶,Yönden Zafer¹

Affiliation:

1. Cukurova University,Department of Medical Biochemistry,Adana,Turkey,

2. Mashhad University of Medical Sciences,Department of Dental Surgery,Mashhad,Iran,

3. Iran University of Medical Sciences,Shahid Motahhari Burn Hospital,,Tehran,Iran,

4. Institute of Natural and Applied Sciences,Department of Biotechnology,Adana,Turkey,

5. University of Tehran,Department of Microbiology and Immunology,Tehran,Iran,

6. Cukurova University,Department of Medical Biochemistry, Faculty of Medicine,Adana,Turkey,

Abstract

Significant findings have been obtained on the relationship between underlying cardiovascular disease and the severity of COVID-19 infection. Using plasma profiles of patients with COVID-19, biomarkers in circulation were also identified that varied depending on the patient's characteristics and disease. The purpose of this study is to review the sources that focus on circulating biomarkers of cardiopulmonary disorders. In addition to conventional biomarkers such as troponin, we consider data from new emerging biomarkers about their roles in the prognosis of severity, mortality in the hospital and effectiveness of treatment. Consideration of mechanisms associated with circulating biomarkers in various conditions associated with COVID-19 can provide broader tools for the diagnosis, treatment, and prognosis of at-risk patients

Publisher

BENTHAM SCIENCE PUBLISHERS

Reference64 articles.

1. Hou H.; Zhang B.; Huang H.; Luo Y.; Wu S.; Tang G.; Liu W.; Mao L.; Mao L.; Wang F.; Sun Z.; Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol 2020,201(1),76-84

2. Mitchell W.B.; Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev 2020,35,20-24

3. Zhang L.; Yan X.; Fan Q.; Liu H.; Liu X.; Liu Z.; Zhang Z.; D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020,18(6),1324-1329

4. Yao Y.; Cao J.; Wang Q.; Shi Q.; Liu K.; Luo Z.; Chen X.; Chen S.; Yu K.; Huang Z.; Hu B.; D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care 2020,8(1),49

5. Samprathi M.; Jayashree M.; Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr 2020,8607647